score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable			Clinical evidence	Somatic Variant	BCOR	Missense	p.N1425S																		Putatively Actionable	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.N1425S (Missense)		A011		
Investigate Actionability - High	FDA-Approved	Guideline	Guideline	Microsatellite Stability	MSI-High								Investigate Actionability - High	Pembrolizumab	Immunotherapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options.	Keytruda [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.; 2018.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125514s041lbl.pdf	Investigate Actionability - High	5-Fluorouracil	Targeted therapy	Patients with MSI-High colorectal cancer appear not to benefit from, and may be resistant to, 5-fluorouracil therapy.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability - High	1	Patients with MSI-High colorectal cancer often have a favorable prognosis.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					MSI-High		A011		
Investigate Actionability - High	Guideline			Mutational Burden	High Mutational Burden								Investigate Actionability - High	Nivolumab + ipilimumab	Immunotherapy	Nivolumab + ipilimumab is an available immunotherapy agent with activity in metastatic, NSCLC patients with high TMB.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 5.2019). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf																 mutations per Mb		A011		
Investigate Actionability - High	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.V45fs*7						Investigate Actionability - High	AZD8186	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability - High	Pembrolizumab	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability - Low	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.V45fs*7 (Frameshift)		A011		
Investigate Actionability - High	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.R108H						Investigate Actionability - High	Pictilisib	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828							Investigate Actionability - Low	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.R108H (Missense)		A011		
Investigate Actionability - Low			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.T41A																		Investigate Actionability - Low	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.T41A (Missense)		A011		
